<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Revive Therapeutics Expands into Phase III Clinical Trials
Image Overlay - Revive Therapeutics Expands into Phase III Clinical Trials

Revive Therapeutics Expands into Phase III Clinical Trials

August 26, 2020

Revive Therapeutics Expands into Phase III Clinical Trials

Revive Therapeutics will expand their candidate, Bucillamine, in patients with mild-moderate COVID-19 in phase III trials taking place in the Asia-Pacific Countries (“APAC”) and Canada. Revive expects to open the Phase 3 clinical trial for patient enrollment and dosing in September 2020. Yourway has a depot in Mississauga, Ontario in Canada, as well as in Beijing, China, Tokyo, Japan, Singapore, and Adelaide, Australia.

Back to Index
Media

Upcoming Events

Precision in Clinical Trials Summit (Boston)

May 6-7, 2024
Hilton Boston Park Plaza

Global Clinical Trial Innovation, Challenges, and Perspectives

June 6, 2024
Yourway's EU Flagship Depot in Dublin, Ireland

Media

Articles

Regulatory barriers in cross-border European pharmaceutical transport

Open chat
Come chat with us!
Hello! How can I help you?